Nanomedicine for diabetes treatment

Bibliography

• 1  Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract.87(1),4–14 (2010).
  Medline CASGoogle Scholar
• 2  Carino GP, Mathiowitz E. Oral insulin delivery. Adv. Drug Del. Rev.35(2–3),249–257 (1999).
  Medline CASGoogle Scholar
• 3  Clore J, Thurby-Hay L. Basal insulin therapy. Curr. Diab. Rep.4(5),342–345 (2004).
  MedlineGoogle Scholar
• 4  Arbit E, Kidron M. Oral insulin: the rationale for this approach and current developments. J. Diabetes Sci. Technol.3(3),562–567 (2009).
  MedlineGoogle Scholar
• 5  Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care7(2),188–199 (1984).
  MedlineGoogle Scholar
• 6  Ward PD, Tippin TK, Thakker DR. Enhancing paracellular permeability by modulating epithelial tight junctions. Pharm. Sci. Tech. Today3(10),346–358 (2000).
  Medline CASGoogle Scholar
• 7  Feng SS. New-concept chemotherapy by nanoparticles of biodegradable polymers: where are we now? Nanomedicine (Lond.)1(3),297–309 (2006).
  CASGoogle Scholar
• 8  Feng SS. Nanomedicine: nanoparticles of biodegradable polymers for cancer diagnosis and treatment. COSMOS – Interdiscipl. J. Sci. Singa. Natl Acad. Sci.4(2),185–201 (2008).
  Google Scholar
• 9  Gershonov E, Goldwaser I, Fridkin M, Shechter Y. A novel approach for a water-soluble long-acting insulin prodrug: design, preparation, and analysis of [(2-sulfo)-9-fluorenylmethoxycarbonyl]3-insulin. J. Med. Chem.43(13),2530–2537 (2000).
  Medline CASGoogle Scholar
• 10  Calceti P, Salmaso S, Walker G, Bernkop-Schnürch A. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci.22(4),315–323 (2004).
  Medline CASGoogle Scholar
• 11  Scott-Moncrieff JC, Shao Z, Mitra AK. Enhancement of intestinal insulin absorption by bile salt–fatty acid mixed micelles in dogs. J. Pharm. Sci.83(10),1465–1469 (1994).
  Medline CASGoogle Scholar
• 12  Wang B, Ma R, Liu G et al. Glucose-Responsive micelles from self-assembly of poly(ethylene glycol)-b-poly(acrylic acid-co-acrylamidophenylboronic acid) and the controlled release of insulin. Langmuir25(21),12522–12528 (2009).
  Medline CASGoogle Scholar
• 13  Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int. J. Nanomed.6(1),1155–1166 (2011).
  CASGoogle Scholar
• 14  Cui FD, Tao AJ, Cun DM, Zhang LQ, Shi K. Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J. Pharm. Sci.96(2),421–427 (2007).
  Medline CASGoogle Scholar
• 15  Ramesan RM, Sharma CP. Challenges and advances in nanoparticle-based oral insulin delivery. Expert Rev. Med. Devices6(6),665–676 (2009).
  Medline CASGoogle Scholar
• 16  Feng SS, Zhao L, Tang J. Nanomedicine for oral chemotherapy. Nanomedicine (Lond.)6(3),407–410 (2011).
  Google Scholar
• 17  Chaudhury A, Das S. Recent Advancement of chitosan-based nanoparticles for oral controlled delivery of insulin and other therapeutic agents. AAPS Pharm. Sci. Tech.12(1),10–20 (2011).
  Medline CASGoogle Scholar
• 18  Yeh TH, Hsu LW, Tseng MT et al. Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials32(26),6164–6173 (2011).
  Medline CASGoogle Scholar
• 19  Sonaje K, Lin K-J, Wang JJ et al. Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv. Funct. Mater20(21),3695–3700 (2010).
  CASGoogle Scholar
• 20  Lin YH, Chung CK, Chen CT, Liang HF, Chen SC, Sung HW. Preparation of nanoparticles composed of chitosan/poly-r-glutamic acid and evaluation of their permeability through Caco-2 Cells. Biomacromolecules6(2),1104–1112 (2005).
  Medline CASGoogle Scholar
• 21  Lin YH, Mi FL, Chen CT et al. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules8(1),146–152 (2007).
  Medline CASGoogle Scholar
• 22  Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials30(12),2329–2339 (2009).
  Medline CASGoogle Scholar
• 23  Yin L, Ding J, He C, Cui L, Tang C, Yin C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials30(29),5691–5700 (2009).
  Medline CASGoogle Scholar
• 24  Sonaje K, Chen YJ, Chen HL et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(γ-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials31(12),3384–3394 (2010).
  Medline CASGoogle Scholar
• 25  Sonaje K, Lin KJ, Wey SP et al. Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials31(26),6849–6858 (2010).
  Medline CASGoogle Scholar
• 26  Arbit E. The physiological rationale for oral insulin administration. Diabetes Technol. Ther.6(4),510–517 (2004).
  Medline CASGoogle Scholar
• 27  Gossain V. Insulin analogs and intensive insulin therapy in Type 1 diabetes. Int. J. Diabetes Dev. Ctries.23(2),26–36 (2003).
  Google Scholar